<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01551797</url>
  </required_header>
  <id_info>
    <org_study_id>A2750894</org_study_id>
    <nct_id>NCT01551797</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol Formulations.</brief_title>
  <official_title>A Proof of Principal Study to Investigate the Pharmacokinetic Profiles of Sustained Release and Standard Paracetamol Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proof of principle study will evaluate an experimental formulation of paracetamol that
      is being developed for eventual long lasting use. This study is also used for drug safety
      evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median time to reach therapeutic plasma concentration of paracetamol</measure>
    <time_frame>Baseline, 15 min, 30 min, 45 min, 1, 1.5 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, and 18 hours post-treatment</time_frame>
    <description>Time period in hours over which plasma paracetamol concentration is elevated at or above 4 micrograms (μg)/milliliter (mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Baseline, 15 min, 30 min, 45 min, 1, 1.5 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, and 18 hours post-treatment</time_frame>
    <description>Area under the plasma concentration-time curve from zero to 6 hours (AUC 0-6 hours), 12 hours (AUC 0-12 hours) to be determined. AUC0-t : the area under the plasma concentration-time curve from zero to time t when paracetamol remains detectable. AUC0-∞: the area under the plasma concentration time curve from zero and extrapolated to infinity time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Baseline, 15 min, 30 min, 45 min, 1, 1.5 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, and 18 hours post-treatment</time_frame>
    <description>Tmax for paracetamol to be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of elimination (T 1/2)</measure>
    <time_frame>Baseline, 15 min, 30 min, 45 min, 1, 1.5 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, and 18 hours post-treatment</time_frame>
    <description>T 1/2 of paracetamol to be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate (Kel)</measure>
    <time_frame>Baseline, 15 min, 30 min, 45 min, 1, 1.5 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, and 18 hours post-treatment</time_frame>
    <description>Kel of paracetamol to be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Baseline, 15 min, 30 min, 45 min, 1, 1.5 2, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, and 18 hours post-treatment</time_frame>
    <description>Cmax of paracetamol to be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs) and Serious AEs</measure>
    <time_frame>Day 1 through Day 14 (follow-up visit)</time_frame>
    <description>Safety evaluation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Test Sustained Release (SR) Paracetamol (2000 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 2000 mg oral dose of SR paracetamol formulation (2 x 1000 mg) administered with 150 mL of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test SR Paracetamol (1500 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 1500 mg oral dose of SR paracetamol formulation (2 x 750 mg) administered with 150 mL of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Paracetamol (2000 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two single 1000 mg doses of paracetamol (2 x 500 mg/dose) administered orally 6 hours apart, administered with 150 mL of water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 500 mg</intervention_name>
    <description>Standard Paracetamol formulation</description>
    <arm_group_label>Reference Paracetamol (2000 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 1000 mg</intervention_name>
    <description>Paracetamol Sustained Release formulation</description>
    <arm_group_label>Test Sustained Release (SR) Paracetamol (2000 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 750 mg</intervention_name>
    <description>Paracetamol Sustained Release formulation</description>
    <arm_group_label>Test SR Paracetamol (1500 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI): Body Mass Index must be in the range 19-28 kg/m2.

        Exclusion Criteria:

          -  Disease: Current or recurrent disease that could affect the action, absorption,
             elimination or disposition of the study medication or clinical or laboratory
             assessments (e.g. hepatic disorders evidenced by abnormal liver function test,
             hepatitis serology test and liver image studies, renal insufficiency, congestive heart
             failure).

          -  Current or relevant previous history of serious, severe or unstable physical or
             psychiatric illness, any medical disorder that may require treatment or make the
             participant unlikely to fully complete the study, or any condition that presents undue
             risk from the study medication or procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles River Clinical Services Northwest, Inc.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <last_update_submitted>December 6, 2012</last_update_submitted>
  <last_update_submitted_qc>December 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

